Form 4: BioCardia CEO Peter Altman Reports Pre-Planned Stock Purchase

BioCardia, Inc. President and CEO Peter Altman reported a pre-planned acquisition of 100 shares of common stock at $2.21 per share, increasing his direct beneficial ownership to 141,766 shares.

Summary

• Peter Altman, President and CEO, and a Director of BioCardia, Inc. (BCDA), reported a transaction involving the company's common stock.
• The transaction, dated May 30, 2025, was an acquisition of 100 shares of common stock.
• The shares were purchased at a price of $2.21 per share.
• This transaction was executed pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan for the purchase of equity securities.
• Following this reported transaction, Peter Altman directly beneficially owns 141,766 shares of BioCardia, Inc. common stock.

Sentiment

Score: 6

Explanation: Slightly positive due to insider buying, but the very small transaction size and pre-planned nature under Rule 10b5-1 limit its overall significance as a strong signal of conviction or immediate positive news.

Positives

• The transaction represents an insider purchase, which can be viewed as a signal of management's confidence in the company's future prospects.
• The purchase was made under a Rule 10b5-1 plan, indicating a pre-scheduled, non-opportunistic acquisition, which aligns with good corporate governance practices.

Negatives

• The number of shares acquired (100 shares) is very small, which may limit the perceived significance of this insider purchase as a strong signal of conviction.

Risks

• The small size of the insider purchase may not strongly mitigate broader market or company-specific risks.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, such as the one reported, are a routine part of corporate disclosure. While a purchase by a CEO can signal confidence, the small size of this particular transaction, especially when pre-planned under Rule 10b5-1, is generally viewed as a less significant indicator compared to larger, open-market purchases.

Stakeholder Impact

• Shareholders may view this insider purchase, albeit small, as a minor positive signal of management's alignment with shareholder interests and confidence in the company.

Key Dates

Keywords

BioCardia, BCDA, Peter Altman, Insider Trading, Form 4, Stock Purchase, Rule 10b5-1, Common Stock, CEO, Director